SPRC - FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD
2024-06-04 17:32:04 ET
More on psychedelic drug companies
- ATAI: Enormous Potential Upside But No Clarity Yet
- Psychedelics Closer To Commercialization; Compass Far And Away The Leader
- COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript
- Psychedelic stocks mixed as FDA comments on MDMA therapy (update)
- Seelos Therapeutics announces pricing of about $1M registered direct offering & concurrent private placement